- Ajinomoto Bio-Pharma Services and Gene Tools have entered a collaboration to provide early-stage phosphorodiamidate morpholino oligomer (PMO) production with a clear pathway to GLP and GMP manufacturing.
- The partnership combines Gene Tools’ solid-phase small-scale synthesis with Ajinomoto Bio-Pharma’s AJIPHASE® purification and quality control capabilities, supporting a smoother transition from research to clinical development.
Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, has announced a collaboration with Gene Tools, LLC to broaden access to phosphorodiamidate morpholino oligomers (PMOs). PMOs are a class of oligonucleotide therapeutics with potential applications in genetic diseases, including Duchenne muscular dystrophy (DMD).
The collaboration addresses early-stage research needs by combining Gene Tools’ solid-phase synthesis of small, diverse PMO batches with Aji Bio-Pharma’s AJIPHASE® liquid-phase technology for purification and quality control. This approach enables a seamless transition from assay-level research through GLP studies and onward to GMP manufacturing.
“Aji Bio-Pharma is committed to enabling and expediting the development of advanced oligonucleotide therapeutics to improve their effectiveness. Through this collaboration with Gene Tools, we are expanding access to high-quality PMOs at the earliest stages of research, while ensuring a clear pathway into GLP and GMP manufacturing.”
Yasuyuki Otake, Corporate Executive, General Manager, Ajinomoto Bio-Pharma Services Department.
The non-exclusive agreement allows clients to accelerate promising PMO candidates from discovery to clinical development. Gene Tools contributes its long-standing expertise in early-stage synthesis, while Aji Bio-Pharma provides purification and large-scale manufacturing capabilities, ensuring continuity and confidence for researchers and biopharmaceutical partners.
